Advertisement

Dual-phase 18F-fluorocholine PET/CT to detect locoregional recurrence of prostate cancer: comparison between each time point of imaging and a summation scan

      Abstract

      Objectives

      Prostate carcinoma is a major health problem, and routine imaging shows only modest results in detecting and restaging clinically localized prostate cancer recurrence. Recent studies have shown promise of radiolabeled analogues of choline for positron emission tomography (PET) scans in patients of biochemical recurrence and that sequentially incremental Fluorocholine (FCH) uptake is associated with malignancy, whereas decreasing tracer activity suggests a benign aetiology. However, this pattern of tracer uptake has not been fully validated, and no standardized 18F-Fluorocholine (18F-FCH) scan protocol is in place yet. This study aimed to better define the role of dual-phase 18F-FCH PET/computed tomography (CT) imaging using retrospective masked reading focusing on detection of locoregional recurrence/metastasis in patients with biochemical failure after definitive local primary treatment.

      Methods

      A total of 32 subjects were enrolled during the period 04/2010 to 05/2014 with histologically proven prostate cancer that was treated with curative intent and had biochemical recurrence. Early scans and delayed imaging of the pelvis were graded separately by blinded readers. Final evaluation using the combination of information from dual-phase studies as a “summation scan” was also performed. Maximum standardized uptake value was computed using regions of interest constructed over focal hyperactivity. Calculations were performed using Statistical Product and Service Solutions, Version 20 for Windows. A composite reference consisting of histopathology, correlation with other imaging, or serum prostate specific antigen (PSA) trend with clinical follow-up of at least 6 months was used to determine the true disease status of the patient.

      Results

      Early-phase pelvis imaging sensitivity and specificity were calculated to be 73.1% and 90.9%, respectively. Late-phase pelvis imaging sensitivity and specificity were 80.8% and 100%, respectively. Summation scan sensitivity and specificity were 76.9% and 100%, respectively. The odds ratio of having recurrent disease with an uptrend of SUVmax on dual-phase imaging was 33.3. The optimal cutoff value of PSA was 1.85 ng/mL with 80% sensitivity and 62.5% specificity.

      Conclusions

      Single late-phase FCH PET/CT imaging is a reliable scan modality which can detect sites of disease at low levels of PSA which still fulfil the criteria of biochemical recurrence. This will allow clinicians to identify sites for potential biopsy or start locoregional treatment.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bashir MN
        Epidemiology of prostate cancer.
        Asian Pac J Cancer Prev. 2015; 16: 5137-5141
        • Bruce JY
        • Lang JM
        • McNeel DG
        • Liu G
        Current controversies in the management of biochemical failure in prostate cancer.
        Clin Adv Hematol Oncol. 2012; 10: 716-722
        • Stephenson AJ
        • Kattan MW
        • Eastham JA
        • Dotan ZA
        • Bianco FJ
        • Lilja H
        • et al.
        Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition.
        J Clin Oncol. 2006; 24: 3973-3978
        • Roach M
        • Hanks G
        • Thames H
        • Schellhammer P
        • Shipley WU
        • Sokol GH
        • et al.
        Int J Radiat Oncol Biol Phys. 2006; 65: 965-974
        • Hricak H
        • Choyke PL
        • Eberhardt SC
        • Leibel SA
        • Scardino PT
        Imaging prostate cancer: a multidisciplinary perspective.
        Radiology. 2007; 243: 28-53
        • Apolo AB
        • Pandit-Taskar N
        • Morris MJ
        Novel tracers and their development for the imaging of metastatic prostate cancer.
        J Nucl Med. 2008; 49: 2031-2041
        • Oehr P
        • Bouchelouche K
        Imaging of prostate cancer.
        Curr Opin Oncol. 2007; 19: 259-264
        • Al-Tamimi A
        • Tan AE
        • Kwong SY
        • Sam CC
        • Chong A
        • Tan CH
        False-negative bone scan and choline PET/CT study in a case of prostate cancer: the pitfall of the small cell prostate carcinoma variant.
        World J Nucl Med. 2012; 11: 75-78
        • von Eyben FE
        • Kairemo K
        Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer.
        Nucl Med Commun. 2014; 35: 221-230
        • Wondergem M
        • van der Zant FM
        • van der Ploeg T
        • Knol RJ
        A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer.
        Nucl Med Commun. 2013; 34: 935-945
        • Umbehr MH
        • Muntener M
        • Hany T
        • Sulser T
        • Bachmann LM
        The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systemic review and meta-analysis.
        Eur Urol. 2013; 64: 106-117
        • Evangelista L
        • Zattoni F
        • Guttilla A
        • Saladini G
        • Zattoni F
        • Colletti PM
        • et al.
        Choline PET or PET/CT and biochemical relapse of prostate cancer: a systemic review and meta-analysis.
        Clin Nucl Med. 2013; 38: 305-314
        • Cimitan M
        • Bortolus R
        • Morassut S
        • Canzonieri V
        • Garbeglio A
        • Baresic T
        • et al.
        18F-fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.
        Eur J Nucl Med Mol Imaging. 2006; 33: 1387-1398
        • Kwee SA
        • Wei H
        • Sesterhenn I
        • Yun D
        • Coel MN
        Localisation of primary prostate cancer with dual-phase 18F-flurocholine PET.
        J Nucl Med. 2006; 47: 262-269
        • Oprea-Lager DE
        • Vincent AD
        • van Moorselaar RJA
        • Gerritsen WR
        • van den Eertwerg AJM
        • Eriksson J
        • et al.
        Dual-phase PET-CT to differentiate [18F]fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer.
        PLoS One. 2012; 7: e48430
        • Langsteger W
        • Balogova S
        • Huchet V
        • Beheshti M
        • Paycha F
        • Ergot C
        • et al.
        Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading.
        Q J Nucl Med Mol Imaging. 2011; 55: 448-457
        • Zhuang HM
        • Pourdehnnad M
        • Lambright ES
        • Yamamoto A.J.
        • Lanuti M.
        • Li P.
        • et al.
        Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes.
        J Nucl Med. 2001; 42: 1412-1417
        • DeGrado TR
        • Kwee SA
        • Coel MN
        • Coleman RE
        The impact of urinary excretion of (18)F-labeled choline analogs.
        J Nucl Med. 2007; 48: 1225
        • DeGrado TR
        • Coleman RE
        • Wang S
        • Baldwin SW
        • Orr MD
        • Robertson CN
        • et al.
        Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.
        Cancer Res. 2001; 61: 110-117
        • DeGrado TR
        • Baldwin SW
        • Wang S
        • Orr MD
        • Liao RP
        • Friedman HS
        • et al.
        Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers.
        J Nucl Med. 2001; 42: 1805-1814
        • Price DT
        • Coleman RE
        • Liao RP
        • Robertson CN
        • Polascik TJ
        • DeGrado TR
        Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.
        J Urol. 2002; 168: 273-280
        • Beauregard JM
        • Williams SG
        • Degrado TR
        • Roselt P
        • Hicks RJ
        Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer.
        J Med Imaging Radiat Oncol. 2010; 54: 325-332
        • Beheshti M
        • Vali R
        • Waldenberger P
        • Fitz F
        • Nader M
        • Loidl W
        • et al.
        Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study.
        Eur J Nucl Med Mol Imaging. 2008; 35: 1766-1774
        • Beheshti M
        • Vali R
        • Waldenberger P
        • Fitz F
        • Nader M
        • Hammer J
        • et al.
        The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
        Mol Imaging Biol. 2009; 11: 446-454
        • Massaro A
        • Ferretti A
        • Secchiero C
        • Cittadin S
        • Milan E
        • Tamiso L
        • et al.
        Optimising (18)F –choline PET/CT acquisition protocol in prostate cancer patients.
        N Am J Med Sci. 2012; 4: 416-420
        • Steiner C
        • Vees H
        • Zaidi H
        • Wissmeyer M
        • Berrebi O
        • Kossovsky MP
        • et al.
        Three-phase 18F-flurocholine PET/CT in the evaluation of prostate cancer recurrence.
        Nuklearmedizin. 2009; 48: 1-9
        • Kitajima K
        • Murphy RC
        • Nathan MA
        Choline PET/CT for imaging prostate cancer: an update.
        Ann Nucl Med. 2013; 27: 581-591
        • Chondrogiannis S
        • Marzola MC
        • Grassetto G
        • Maffione AM
        • Rampin L
        • Veronese E
        • et al.
        New acquisition protocol of 18F-choline PET/CT in prostate cancer patients: review of the literature about methodology and proposal of standardization.
        Biomed Res Int. 2014; 2014: 10215650
        • Hacker A
        • Jeschke S
        • Leeb K
        • Prammer K
        • Ziegerhofer J
        • Sega W
        • et al.
        Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection.
        J Urol. 2006; 176 ([discussion 8–9]): 2014-2018
        • Brogsitter C
        • Zophel K
        • Kotzerke J
        18F-choline, 11C-choline, and 11C-acetate PET/CT: a comparative analysis for imaging prostate cancer patients.
        Eur J Nucl Med Mol Imaging. 2013; 40: S18-S27
        • Tokuda Y
        • Carlino LJ
        • Gopalan A
        • Tickoo SK
        • Kaag MG
        • Guillonneau B
        • et al.
        Prostate cancer topography and patterns of lymph node metastasis.
        Am J Surg Pathol. 2010; 34: 1862-1867
        • Weckermann D
        • Dorn R
        • Trefz M
        • Wagner T
        • Wawroschek F
        • Harzmann R
        Sentinel lymph node dissection for prostate cancer: experience with more than 1000 patients.
        J Urol. 2007; 177: 916-920